Sutro Biopharma (STRO) Common Equity (2016 - 2026)
Sutro Biopharma (STRO) posted Common Equity of -$132.5 million for Q4 2025, down 51.78% sequentially from -$87.3 million in Q3 2025, and down 396.97% YoY from $44.6 million in Q4 2024.
Sutro Biopharma (STRO) Common Equity (2016 - 2026) Analysis & Trends
Sutro Biopharma has reported Common Equity for 10 years, with the latest figure at -$132.5 million in Q4 2025.
- Quarterly Common Equity fell 396.97% year-over-year to -$132.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.5 million (down 396.97% YoY) and the FY2025 annual result came in at -$132.5 million, down 396.97% from the prior year.
- Common Equity eased to -$132.5 million in Q4 2025 per STRO's latest filing, from -$87.3 million in the prior quarter.
- Over five years, Common Equity peaked at $307.5 million in Q2 2021 and troughed at -$132.5 million in Q4 2025.
- A 5-year average of $137.9 million and a median of $153.4 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity surged 274.41% in 2021, then slumped 396.97% in 2025.
- Over 5 years, Common Equity stood at $252.6 million in 2021, then retreated by 14.06% to $217.0 million in 2022, then tumbled by 31.05% to $149.6 million in 2023, then slumped by 70.2% to $44.6 million in 2024, then tumbled by 396.97% to -$132.5 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$132.5 million, -$87.3 million, and -$32.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | -103.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103.32 Mn |
| Dec 31, 2025 | -132.45 Mn |
| Sep 30, 2025 | -87.27 Mn |
| Jun 30, 2025 | -32.11 Mn |
| Mar 31, 2025 | -25.81 Mn |
| Dec 31, 2024 | 44.60 Mn |
| Sep 30, 2024 | 111.22 Mn |
| Jun 30, 2024 | 152.18 Mn |
| Mar 31, 2024 | 98.02 Mn |
| Dec 31, 2023 | 149.65 Mn |
| Sep 30, 2023 | 112.43 Mn |
| Jun 30, 2023 | 154.72 Mn |
| Mar 31, 2023 | 185.41 Mn |
| Dec 31, 2022 | 217.05 Mn |
| Sep 30, 2022 | 229.73 Mn |
| Jun 30, 2022 | 209.06 Mn |
| Mar 31, 2022 | 220.37 Mn |
| Dec 31, 2021 | 252.56 Mn |
| Sep 30, 2021 | 283.58 Mn |
| Jun 30, 2021 | 307.50 Mn |